Rheumatological Conditions and the Kidney



Systemic sclerosis (SSc) is a debilitating, chronic, systemic, autoimmune disease of unknown cause. It is classified as limited or diffuse dependent on skin involvement. The incidence and prevalence of SSc vary in different populations where it seems to be more prevalent in the United States (286 cases per million adults) than in Europe (31 cases per million adults) with an annual incidence of 1–20 cases per million. SSc is three times more common in females than males and typically presents between the ages of 30 and 60 years. Typical skin features of SSc are well described and include skin thickening, sclerodactyly, finger pulp pitting, fingertip ulceration, digital gangrene and telangiectasia; some of which are illustrated in Figs. 27.1 and 27.2. SSc causes vascular damage, immune activation and inflammation, culminating in fibrosis which is responsible for the clinical manifestations of the disease. Table 27.1 summarizes the prevalence of extrarenal clinical manifestations seen in SSc.


Ankylose Spondylitis Acute Kidney Injury Renal Tubular Acidosis Inclusion Body Myositis Mixed Connective Tissue Disease 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Batal I, Domsic RT, Shafer A, Medsger Jr TA, Kiss LP, Randhawa P, Bastacky S. Renal biopsy findings predicting outcome in scleroderma renal crisis. Hum Pathol. 2009;40(3):332–40.PubMedCrossRefGoogle Scholar
  2. 2.
    Moinzadeh P, Nihtyanova SI, Howell K, Ong VH, Denton CP. Impact of hallmark autoantibody reactivity on early diagnosis in scleroderma. Clin Rev Allergy Immunol. 2012;43(3):249–55.PubMedCrossRefGoogle Scholar
  3. 3.
    Penn H, Howie AJ, Kingdon EJ, Bunn CC, Stratton RJ, Black CM, et al. Scleroderma renal crisis: patient characteristics and long-term outcomes. QJM. 2007;100(8):485–94.PubMedCrossRefGoogle Scholar
  4. 4.
    Uda H, Yokota A, Kobayashi K, et al. Two distinct courses of renal involvement in rheumatoid patients with AA amyloidosis. J Rheumatol. 2006;33:1482–7.PubMedGoogle Scholar
  5. 5.
    Nakamura T, Higashi S, Tomoda K, Tsukano M, Baba S. Efficacy of etanercept in patients with AA amyloidosis secondary to rheumatoid arthritis. Clin Exp Rheumatol. 2007;25(4):518–22.Google Scholar

Copyright information

© Springer-Verlag London 2014

Authors and Affiliations

  1. 1.Rheumatology DepartmentRoyal Free HospitalLondonUK
  2. 2.UCL Department of NephrologyRoyal Free London NHS Foundation TrustHampstead, LondonUK

Personalised recommendations